Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Dong-A ST

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Aricept 10mg Tablet; Drug: Aricept 5mg Tablet; Drug: DA-5207 A; Drug: DA-5207 B

Study type: Interventional

Funder types: Industry

Identifiers

NCT05127746

DA5207_AD2_Ib

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

Enrollment: 51 patients

Sex: All

Ages: 19 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Health Volunteers (Age: 19~55 years)
• Body Weight: Male≥55kg, Female≥50kg
• 18.5 ≤BMI≤ 25.0

Exclusion criteria

• Galactose intolerance, Lapp lactase deficiency, Glucose-galactose malabsorption
• Allergy or Drug hypersensitivity
• Clinically significant Medical History
• AST, ALT>Upper Normal Range*1.25, eGFR<60mL/min/1.73m²
• Heavy caffeine intake
• Heavy alcohol intake (more than 210g/week)
• Heavy smoker (more than 10 cigarettes/day)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

51 participants in 4 patient groups

Sequence 1

Experimental group

Description:

Period 1, Aricept 5mg → DA-5207 A; Period 2, Aricept 5mg → Aricept 10mg

Treatment:

Drug: Aricept 10mg Tablet

Drug: Aricept 5mg Tablet

Drug: DA-5207 A

Sequence 2

Experimental group

Description:

Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 A

Treatment:

Drug: Aricept 10mg Tablet

Drug: Aricept 5mg Tablet

Drug: DA-5207 A

Sequence 3

Experimental group

Description:

Period 1, Aricept 5mg → DA-5207 B; Period 2, Aricept 5mg → Aricept 10mg

Treatment:

Drug: Aricept 10mg Tablet

Drug: Aricept 5mg Tablet

Drug: DA-5207 B

Sequence 4

Experimental group

Description:

Period 1, Aricept 5mg → Aricept 10mg; Period 2, Aricept 5mg → DA-5207 B

Treatment:

Drug: Aricept 10mg Tablet

Drug: Aricept 5mg Tablet

Drug: DA-5207 B